![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 3
2021
Duell, Johannes; Maddocks, Kami J.; Gonzalez-Barca, Eva; Jurczak, Wojciech; Liberati, Anna Marina; de Vos, Sven; Nagy, Zsolt; Obr, Ales; Gaidano, Gianluca; Abrisqueta, Pau; Kalakonda, Nagesh; Andre, Marc; Dreyling, Martin; Menne, Tobias; Tournilhac, Olivier; Augustin, Marinela; Rosenwald, Andreas; Dirnberger-Hertweck, Maren; Weirather, Johannes; Ambarkhane, Sumeet und Salles, Gilles
(2021):
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
In: Haematologica, Bd. 106, Nr. 9: S. 2417-2426
Schmitz, Norbert; Truemper, Lorenz; Bouabdallah, Krimo; Ziepert, Marita; Leclerc, Mathieu; Cartron, Guillaume; Jaccard, Arnaud; Reimer, Peter; Wagner, Eva; Wilhelm, Martin; Sanhes, Laurence; Lamy, Thierry; de Leval, Laurence; Rosenwald, Andreas; Roussel, Muriel; Kroschinsky, Frank; Lindemann, Walter; Dreger, Peter; Viardot, Andreas; Milpied, Noeel; Gisselbrecht, Christian; Wulf, Gerald; Gyan, Emmanuel; Gaulard, Philippe; Bay, Jacques Olivier; Glass, Bertram; Poeschel, Viola; Damaj, Gandhi; Sibon, David; Delmer, Alain; Bilger, Karin; Banos, Anne; Haenel, Mathias; Dreyling, Martin; Metzner, Bernd; Keller, Ulrich; Braulke, Friederike; Friedrichs, Birte; Nickelsen, Maike; Altmann, Bettina und Tournilhac, Olivier
(2021):
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
In: Blood, Bd. 137, Nr. 19: S. 2646-2656
2020
Salles, Gilles; Duell, Johannes; Gonzalez Barca, Eva; Tournilhac, Olivier; Jurczak, Wojciech; Liberati, Anna Marina; Nagy, Zsolt; Obr, Ales; Gaidano, Gianluca; Andre, Marc; Kalakonda, Nagesh; Dreyling, Martin; Weirather, Johannes; Dirnberger-Hertweck, Maren; Ambarkhane, Sumeet; Fingerle-Rowson, Gunter und Maddocks, Kami
(2020):
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
In: Lancet Oncology, Bd. 21, Nr. 7: S. 978-988